HYDROXYCHLOROQUINE SULFATE FORMULATIONS AND METHODS FOR PREPARATION AND USE THEREOF

    公开(公告)号:US20200297636A1

    公开(公告)日:2020-09-24

    申请号:US16650965

    申请日:2018-10-11

    Abstract: Water-dispersible pharmaceutical compositions of hydroxychloroquine sulfate in powder or granule form are provided that allow for ease of preparation of measured-dose, liquid suspensions that are palatable and suitable for pediatric administration. The compositions in granular or powder form are efficiently dissolvable in water and can be provided encapsulated within a two-piece releasable hard capsule or a packet or pouch for easy release. An ion-pairing agent is present in the formulation of the composition that masks the bitter taste of the hydroxychloroquine sulfate, significantly reducing the need for addition of a sweetening agent. Methods are provided for preparing the water-dispersible pharmaceutical compositions of hydroxychloroquine sulfate and for preparing palatable weight-based pediatric doses.

    Fiber sampler for recovery of bioaerosols and particles

    公开(公告)号:US10767210B2

    公开(公告)日:2020-09-08

    申请号:US16455067

    申请日:2019-06-27

    Abstract: An aerosol collection system and method. The system includes a bio-aerosol delivery device configured to supply bioparticles in a gas stream, a moisture exchange device including a partition member coupled to the gas stream and configured to humidify or dehumidify the bioparticles in the gas stream, and an aerosol collection medium downstream from the moisture exchange device and configured to collect the bioparticles. The method includes delivering bioparticles in a gas stream, humidifying or dehumidifying the bioparticles in the gas stream by transport of water across a partition member and into a vapor phase of the gas stream, and collecting the bioparticles by a collection medium.

    ROTATING PACKED BEDS WITH INTERNAL HEAT TRANSFER FOR ABSORPTION/REGENERATION APPLICATIONS

    公开(公告)号:US20200261846A1

    公开(公告)日:2020-08-20

    申请号:US16792246

    申请日:2020-02-16

    Abstract: A gas-liquid contacting apparatus and method are described, in which at least one rotor assembly including packing is arranged in a contacting chamber containing at least one stator assembly including at least one heat exchanger arranged to thermally modulate the gas-liquid contacting so that each stator assembly is operatively arranged with each stator assembly to provide gas-liquid contacting at temperatures effective for mass exchange between the gas and liquid. The rotor and stator assemblies may be of annular shape, or may be of disk shape in a stacked array of rotor assemblies alternating with stator assemblies. Such apparatus and method are usefully employed for CO2 capture from CO2-containing flue gases such as combustion effluents from power generation plants.

    HIGH EFFICIENCY NEUTRON CAPTURE PRODUCT PRODUCTION

    公开(公告)号:US20200035373A1

    公开(公告)日:2020-01-30

    申请号:US16580311

    申请日:2019-09-24

    Abstract: An apparatus for use with a neutron source for producing reaction-product nuclei from reactant nuclei includes a plurality of reactant nuclei and a plurality of moderating nuclei. The reactant nuclei and the moderating nuclei are configured to increase the probability of neutron capture by reactant nuclei to achieve enhanced ratios of neutron capture by reactant nuclei to neutron source neutron production. Moderating nuclei and neutron reflection are used to minimize neutron leakage. Temperature control, including cryogenic temperature control, may be used to enhance the rate or probability of reactant nuclei neutron capture. The reactant nuclei may include molybdenum-98 and reaction-product nuclei may include technetium-99m.

    DIARYL PURINE DERIVATIVES WITH IMPROVED BIOAVAILABILITY

    公开(公告)号:US20190352305A1

    公开(公告)日:2019-11-21

    申请号:US16472155

    申请日:2017-12-20

    Abstract: This disclosure is directed to various compounds and methods of preparation of improved compounds that are capable of functioning as cannabinoid receptor 1 (CB1) antagonists with reduced central nervous system (CNS) side effects. The application is also directed to pharmaceutical compositions containing one or more of these compounds, which may also contain one or more additional therapeutic agents. It is also directed to methods of treatment of various conditions that may be responsive to antagonism of the CB1 receptors, including, but not limited to, metabolic syndromes (including liver disease, obesity, and diabetes).

Patent Agency Ranking